Article

How Can Pharma Companies Join the Digital Therapeutics Revolution?

Guidehouse’s Maya Desai and Andrew Fraser address the various steps digital therapeutics companies should be considering as they build their launch playbooks beyond the traditional commercial activities.

By Maya Desai and Andrew Fraser, Guidehouse

More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement. Guidehouse’s Maya Desai and Andrew Fraser address the various steps digital therapeutics companies should be considering as they build their launch playbooks beyond the traditional commercial activities.

Read the full article in PharmExec

Maya Desai, Director

Andrew Fraser, Associate Director

Let Us Help Guide You

Complexity demands a trusted guide with the unique expertise and cross-sector versatility to deliver unwavering success. We work with organizations across regulated commercial and public sectors to catalyze transformation and pioneer new directions for the future.

How Can Pharma Companies Join the Digital Therapeutics Revolution?

Guidehouse’s Maya Desai and Andrew Fraser address the various steps digital therapeutics companies should be considering as they build their launch playbooks beyond the traditional commercial activities.

Writers and Contributors

Let Us Help Guide You

Stay ahead of the curve with news, insights and updates from Guidehouse about issues relevant to your organization and its work.